Related Experiment Video
Updated: May 4, 2026
Minimally Invasive Thumb-sized Pterional Craniotomy for Surgical Clip Ligation of Unruptured Anterior Circulation Aneurysms
Published on: August 11, 2015
Antithrombotic Therapy in Cerebral Cavernous Malformations: A Systematic Review, Meta-Analysis, and Network
Basel Musmar1, Hamza Salim2, Jihad Abdelgadir1
1Department of Neurosurgery Duke University Hospital Durham NC USA.
Insights
Antithrombotic therapy may reduce intracranial hemorrhage risk in cerebral cavernous malformations. This systematic review found lower hemorrhage rates in patients using antiplatelet or anticoagulant medications, though findings are preliminary.
Area of Science:
- Neurology
- Vascular Medicine
- Pharmacology
Background:
- Cerebral cavernous malformations (CCMs) are CNS vascular anomalies posing hemorrhage risks.
- Antithrombotic therapy use in CCMs is debated due to bleeding concerns.
- Emerging evidence suggests potential benefits of antithrombotic agents in CCMs.
Approach:
- Systematic review and meta-analysis of 9 nonrandomized cohort studies (2709 patients).
- Searched PubMed, Web of Science, and Scopus databases.
- Analyzed outcomes using random-effects model and network meta-analysis.
Key Points:
- Antithrombotic therapy associated with significantly lower risk of presenting intracranial hemorrhage (OR 0.56).
- Antithrombotic use linked to reduced follow-up hemorrhage risk from CCMs (OR 0.21).
- Network meta-analysis showed no significant difference between antiplatelet and anticoagulant therapy (OR 0.73).
Conclusions:
- Antithrombotic therapy may offer protective benefits in cerebral cavernous malformations.
- Study findings are preliminary and hypothesis-generating due to study design limitations.
- Further research is needed before clinical practice changes can be recommended.
Background:
Cerebral cavernous malformations are complex vascular anomalies in the central nervous system associated with a risk of intracranial hemorrhage. Traditional guidelines have been cautious about the use of antithrombotic therapy in this patient group, citing concerns about potential bleeding risk. However, recent research posits that antithrombotic therapy may actually be beneficial. This study aims to clarify the association between antithrombotic therapy, including antiplatelet and anticoagulant medications, and the risk of intracranial hemorrhage in patients with cerebral cavernous malformations.
Methods And Results:
A comprehensive literature search was conducted in PubMed, Web of Science, and Scopus databases, following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Nine single-center, nonrandomized cohort studies involving 2709 patients were included. Outcomes were analyzed using random-effects model, and a network meta-analysis was conducted for further insight. Of the 2709 patients studied, 388 were on antithrombotic therapy. Patients on antithrombotic therapy had a lower risk of presenting with intracranial hemorrhage (odds ratio [OR], 0.56 [95% CI, 0.45-0.7]; P<0.0001). In addition, the use of antithrombotic therapy was associated with lower risk of intracranial hemorrhage from a cerebral cavernous malformation on follow-up (OR, 0.21 [95% CI, 0.13-0.35]; P<0.0001). A network meta-analysis revealed a nonsignificant OR of 0.73 (95% CI, 0.23-2.56) when antiplatelet therapy was compared with anticoagulant therapy.
Conclusions:
Our study explores the potential benefits of antithrombotic therapy in cerebral cavernous malformations. Although the analysis suggests a possible role for antithrombotic agents, it is critical to note that the evidence remains preliminary. Fundamental biases in study design, such as ascertainment and assignment bias, limit the weight of our conclusions. Therefore, our findings should be considered hypothesis-generating and not definitive for clinical practice change.
